Quantitative in situ analysis of β-catenin expression in breast cancer shows decreased expression is associated with poor outcome

Cancer Research

Volumn 66, Issue 10, 2006, Pages 5487-5494

  Dolled Filhart, Marisa ^a   McCabe, Anthony ^a   Giltnane, Jennifer ^a   Cregger, Melissa ^a   Camp, Robert L ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; COMPUTER PROGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ALGORITHMS; BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MICROARRAY ANALYSIS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33744938180     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0100     Document Type: Article

References (38)

1. Hatsell S, Rowlands T, Hiremath M, Cowin P. β-Catenin and Tcfs in mammary development and cancer. j Mammary Gland Biol Neoplasia 2003;8:145-58.
2. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-51.
3. Candidus S, Bischoff P, Becker KF, Hofler H. No evidence for mutations in the α- and β-catenin genes in human gastric and breast carcinomas. Cancer Res 1996; 56:49-52.
4. Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther 2004;3:36-41.
5. Brown AM. Wnt signaling in breast cancer: have we come full circle? Breast Cancer Res 2001;3:351-5.
6. Dillon D, Johnson C, Rimm DL, Costa J. K-ras mutational analysis as a routine adjunct in the cytologic diagnosis of pancreatobiliary neoplasms. Lab Invest 1998;78:37a.
7. Nakopoulou L, Gakiopoulou H, Keramopoulos A, et al. c-Met tyrosine kinase receptor expression is associated with abnormal β-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 2000;36:313-25.
8. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, et al. Expression patterns of β-catenin in in situ and invasive breast cancer. Eur J Surg Oncol 2001;27:31-6.
9. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL, E-cadherin and α-, β-, and γ-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998;185:262-6.
10. Bankfalvi A, Terpe HJ, Breukelmann D, et al. Immunophenotypic and prognostic analysis of E-cadherin and β-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999;34:25-34.
11. Lin SY, Xia W, Wang JC, et al. β-Catenin, a novel prognostic marker for breast cancer: its roles in cyclin Dl expression and cancer progression. Proc Natl Acad Sci U S A 2000;97:4262-6.
12. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8: 1323-7.
13. Bondi J, Bukholm G, Nesland JM, Bukholm IR. Expression of non-membranous β-catenin and γ-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 2004;112:49-56.
14. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC. Nat Cell Biol 2001;3:793-801.
15. Pedersen KB, Nesland JM, Fodstad O, Maelandsmo GM. Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies. Br J Cancer 2002;87:1281-6.
16. Wong SC, Lo SF, Lee KC, et al. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol 2002;196:145-53.
17. Gillett CE, Miles DW, Ryder K, et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 2001;193:433-41.
18. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 1986;55:244-8.
19. Wan WH, Fortuna MB, Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods 1987;103:121-9.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
21. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
22. Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003;16:79-84.
23. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-56.
24. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
25. Dolled-Filhart M, Rimm DL. Tissue arrays. 7th ed. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 26-34.
26. Dolled-Filhart MP, Rimm DL. Tissue microarray technology: a new standard for molecular evaluation of tissue? Princ Pract Oncol Technol Update 2002;16: 1-11.
27. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;63:1445-8.
28. Chung GG, Zerkowski MP, Ocal IT, et al. β-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 2004;100:2084-92.
29. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003;9:594-600.
30. Kang JY, Dolled-Filhart M, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003;63:1101-5.
31. Kluger HM, Dolled-Filhart M, Rodov S, et al. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 2004;10:173-7.
32. Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003;97:1841-8.
33. Shigemitsu K, Sekido Y, Usami N, et al. Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 2001;20:4249-57.
34. Smalley MJ, Dale TC. Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 1999; 18:215-30.
35. Smalley MJ, Dale TC. Wnt signaling and mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2001;6: 37-52.
36. Imbert A, Eelkema R, Jordan S, Feiner H, Cowin P, ΔN89 β-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol 2001;153:555-68.
37. Gonzalez-Sancho JM, Brennan KR, Castelo-Soccio LA, Brown AM. Wnt proteins induce dishevelled phosphorylation via an LRP5/6-independent mechanism, irrespective of their ability to stabilize β-catenin. Mol Cell Biol 2004;24:4757-68.
38. Kielhorn E, Provost E, Olsen D, et al. Tissue microarray-based analysis shows phospho-β-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 2003;103:652-6.